Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

RevenueShares Navellier Overall A-100 Fund (RWV)

Delayed Data
As of Sep 01
 -0.76 / -1.58%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to outperform the total return performance of the Navellier Overall A-100 Index, the fund's benchmark index. The fund attempts to replicate the portfolio of the RevenueShares Navellier Overall A-100 IndexTM (the "underlying index"). The underlying index is constructed by re-weighting the constituent securities of the benchmark index according to the revenue earned by the companies in the benchmark index, subject to certain asset diversification requirements and a maximum 7% per company weighting. The fund will invest at least 80% of its net assets in companies included in the benchmark index. It is non-diversified.

No recent news for RevenueShares Navellier Overall A-100 Fund.


1 month-8.75% 3 years+12.92%
3 months-9.23% 5 years+14.14%
1 year-1.50% Since inception+14.26%
Data through 09/02/2015

Quote Details

Previous close$48.01
Open day’s range47.10 – 47.25
Net asset value (NAV)46.72 (09/01/2015)
Daily volume450
Average volume (3 months)837
Data as of 09/01/2015

Peer Comparisonvs. Mid-cap growth ETFs

Performance 5-yr return+14.14%+17.66%
Expense Gross exp ratio1.37%0.49%
Risk 5 year sharpe ratio1.001.14
Net assets$7.7M$1.4B
Average market cap$18.7B$9.8B
Average P/E21.025.2
Dividend / Share--0.15%


VOT Vanguard Mid-Cap Growth Index Fund ETF S...
IWP iShares Russell Mid-Cap Growth ETF
PXMG PowerShares Russell Midcap Pure Growth P...


Top 5 Sectors
Portfolio weighting
Consumer goods 39.43%
Consumer service 20.60%
Hardware 9.08%
Industrial materials 7.23%
Financial service 5.28%
Top 10 Holdings
Portfolio weighting
KR Kroger Co7.47%
UNH UnitedHealth7.09%
TGT Target6.91%
AAPL Apple6.80%
MCK McKesson Corp6.64%
ANTM WellPoint6.63%
AET Aetna5.37%
GILD Gilead Sciences2.88%
CNC Centene Corp1.84%
BMY Bristol-Myers Squibb1.82%

Partner Offers